These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22831473)

  • 1. Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.
    Leuenberger N; Reichel C; Lasne F
    Bioanalysis; 2012 Jul; 4(13):1565-75. PubMed ID: 22831473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples.
    Leuenberger N; Saugy J; Mortensen RB; Schatz PJ; Giraud S; Saugy M
    Forensic Sci Int; 2011 Dec; 213(1-3):15-9. PubMed ID: 21816551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to confirm C.E.R.A. doping in athletes' blood?
    Leuenberger N; Lamon S; Robinson N; Giraud S; Saugy M
    Forensic Sci Int; 2011 Dec; 213(1-3):101-3. PubMed ID: 21889277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical challenges in the detection of peptide hormones for anti-doping purposes.
    Barroso O; Handelsman DJ; Strasburger C; Thevis M
    Bioanalysis; 2012 Jul; 4(13):1577-90. PubMed ID: 22831474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sports drug testing for erythropoiesis-stimulating agents and autologous blood transfusion.
    Reichel C
    Drug Test Anal; 2012 Nov; 4(11):803-4. PubMed ID: 22927317
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of peptidic erythropoiesis-stimulating agents in sport.
    Reichel C
    Br J Sports Med; 2014 May; 48(10):842-7. PubMed ID: 24677025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of darbepoetin alfa in human plasma by liquid chromatography coupled to mass spectrometry for doping control.
    Guan F; Uboh CE; Soma LR; Birksz E; Chen J
    Int J Sports Med; 2009 Feb; 30(2):80-6. PubMed ID: 19177313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OMICS-strategies and methods in the fight against doping.
    Reichel C
    Forensic Sci Int; 2011 Dec; 213(1-3):20-34. PubMed ID: 21862249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-throughput test to detect C.E.R.A. doping in blood.
    Lamon S; Giraud S; Egli L; Smolander J; Jarsch M; Stubenrauch KG; Hellwig A; Saugy M; Robinson N
    J Pharm Biomed Anal; 2009 Dec; 50(5):954-8. PubMed ID: 19625154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc-fragment removal allows the EPO-Fc fusion protein to be detected in blood samples by IEF-PAGE.
    Postnikov P; Krotov G; Mesonzhnik N; Efimova Y; Rodchenkov G
    Drug Test Anal; 2015; 7(11-12):999-1008. PubMed ID: 26695487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry.
    Yu NH; Ho EN; Wan TS; Wong AS
    Anal Bioanal Chem; 2010 Apr; 396(7):2513-21. PubMed ID: 20148243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review.
    Girard M; Puerta A; Diez-Masa JC; de Frutos M
    Anal Chim Acta; 2012 Feb; 713():7-22. PubMed ID: 22200302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in doping testing for erythropoietin.
    Reichel C
    Anal Bioanal Chem; 2011 Aug; 401(2):463-81. PubMed ID: 21637931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin and erythropoiesis stimulating agents.
    Debeljak N; Sytkowski AJ
    Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood doping: risks to athletes' health and strategies for detection.
    Oliveira CD; Bairros AV; Yonamine M
    Subst Use Misuse; 2014 Jul; 49(9):1168-81. PubMed ID: 24766400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications and biomonitoring issues of recombinant erythropoietins for doping control.
    Tsitsimpikou C; Kouretas D; Tsarouhas K; Fitch K; Spandidos DA; Tsatsakis A
    Ther Drug Monit; 2011 Feb; 33(1):3-13. PubMed ID: 21099742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control.
    Reichel C; Kulovics R; Jordan V; Watzinger M; Geisendorfer T
    Drug Test Anal; 2009 Jan; 1(1):43-50. PubMed ID: 20355158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity and specificity of detection methods for erythropoietin doping in cyclists.
    Heuberger JAAC; van Eenoo P; Rotmans JI; Gal P; Stuurman FE; Post TE; Daniels JMA; Ram H; de Hon O; Burggraaf J; Cohen AF
    Drug Test Anal; 2019 Sep; 11(9):1290-1301. PubMed ID: 31232530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse of medicines for performance enhancement in sport: why is this a problem for the pharmaceutical industry?
    Elliott S; Leishman B
    Bioanalysis; 2012 Jul; 4(13):1681-90. PubMed ID: 22831483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GASepo-a software solution for quantitative analysis of digital images in Epo doping control.
    Bajla I; Holländer I; Minichmayr M; Gmeiner G; Reichel Ch
    Comput Methods Programs Biomed; 2005 Dec; 80(3):246-70. PubMed ID: 16260062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.